Related Experiment Videos
Thrombospondins and tumor angiogenesis.
F de Fraipont1, A C Nicholson, J J Feige
1INSERM EMI 0105, Dept of Molecular and Structural Biology, Commissariat à l'Energie Atomique, Grenoble, France.
Trends in Molecular Medicine
|September 1, 2001
Summary
Thrombospondins (TSPs) are proteins with anti-angiogenic properties. TSPs and their derived peptides show potential as novel therapeutic strategies for treating solid tumors by inhibiting blood vessel formation.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Thrombospondins (TSPs) are secreted proteins found in the extracellular matrix.
- TSPs are multimodular, with domains mediating specific biological functions via receptor interactions.
- TSP1 and TSP2 exhibit anti-angiogenic activity, partly through CD36 receptor binding.
Purpose of the Study:
- To explore the role of TSPs in tumor biology.
- To investigate the therapeutic potential of TSPs and TSP-derived peptides for anti-angiogenic cancer treatment.
Main Methods:
- Analysis of TSP expression patterns in various tumor types.
- Investigation of TSP-receptor interactions, specifically TSP1 and CD36.
- Review of studies on TSP expression modulation by hypoxia and oncogenes.
Main Results:
- TSP1 and TSP2 expression is influenced by hypoxia and oncogenes.
- TSP1 expression shows varied prognostic value across different cancers (e.g., inverse correlation in thyroid, colon, bladder; limited value in breast).
- Recent research highlights TSPs and TSP-derived peptides as potential anti-angiogenic therapeutics.
Conclusions:
- TSPs play a complex role in cancer, with varying prognostic significance.
- The anti-angiogenic properties of TSPs, particularly TSP1, offer a promising avenue for developing new cancer therapies.